Program
ENPP1 Inhibitor RBS2418
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Hepatocellular · Neoplasm Metastasis, led by Riboscience, LLC..
Furthest: phase 2, since Jan 30, 20253 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Riboscience, LLC. | 33 open or running | phase 2since Jan 30, 2025 | Feb 9, 2022 | Apr 2027phase 2 · NCT07175441 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2022First study: phase 1 study in Neoplasm MetastasisFirst studyNCT05270213 · 164 planned · United States
- Jan 30, 2025Phase 2 study in Colorectal NeoplasmsNCT06824064 · 150 planned · United States, Puerto Rico, Vietnam
- Sep 9, 2025Phase 2 study in Advanced Unresectable Hepatocellular CarcinomaNCT07175441 · 220 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Advanced Unresectable Hepatocellular CarcinomaNCT07175441
- Apr 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT05270213
- Dec 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06824064
TargetBeta
ENPP1 →read by rule
“A selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), ”NCIt, by rule
Other programs on ENPP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TXN10128rule | txinno-bioscience-inc | phase 2 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07175441Advanced Unresectable Hepatocellular Carcinoma · United States | 2 | Recruiting | Apr 2027 | 220 |
| NCT06824064Colorectal Neoplasms · United States, Puerto Rico, Vietnam | 2 | Recruiting | Dec 2027 | 150 |
| NCT05270213Neoplasm Metastasis · United States | 1 | Recruiting | Apr 2027 | 164 |
How it is read
Names in the registry
- “RBS2418”, 3 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.